School of Pharmacy

David Veenstra

Professor and Associate Director, Comparative Health Outcomes, Policy & Economics (CHOICE) Institute

CHOICE Faculty, Department of Pharmacy, Pharmacogenomics Research Network, Pharmacy Faculty, School Faculty

Telephone: 206.221.6936


Office Location: H375-P


  • PharmD, University of California, San Francisco
  • PhD in Pharmaceutical Chemistry, University of California, San Francisco

Research Interests

  • Precision medicine
  • Cost-effectiveness analysis
  • Managed care decision making

Courses Taught

  • Pharm 520: Introduction to Pharmacoeconomics
  • Pharm 542: Managed Care Pharmacy


Dr. Veenstra is a Professor in the Department of Pharmacy and Associate Director of the Comparative Health Outcomes, Policy & Economics (CHOICE) Institute. He graduated from the University of California San Francisco with doctoral degrees in clinical pharmacy and computational chemistry. He conducted his postdoctoral training in health economics and outcomes research with the University of Washington, including a one-year externship with Roche Global Pharmacoeconomics.

Dr. Veenstra’s primary research interests are the clinical, economic, and policy implications of using genomic information in healthcare. His major research projects include evaluation of the cost effectiveness of population-level genomic screening, pharmacogenomics in diverse populations, decision modeling techniques to assess evidence thresholds, and stakeholder preferences for precision medicine.

Dr. Veenstra’s research has been funded through grants from the National Human Genome Research Institute, Centers for Disease Control, National Cancer Institute, and the National Institute for General Medical Sciences.

Dr. Veenstra has worked extensively with organizations such as the Academy of Managed Care Pharmacy (AMCP) and the Institute for Clinical and Economic Review (ICER) to further the practical application of cost-effectiveness analysis in managed care decision making.

Dr. Veenstra teaches courses in pharmacoeconomics and managed care and is an author or co-author of five book chapters and over 180 peer-reviewed publications.

Selected Publications

  1. Guzauskas GF, Basu A, Veenstra DL. Are there different evidence thresholds for genomic vs. clinical precision medicine? A VOI-based framework applied to antiplatelet drug therapy. Value in Health, in press, 2019.
  2. Henderson LM, Robinson RF, Ray L, Li T, Dillard DA, Schilling BD, Mosley M, Janssen PL, Fohner AE, Rettie AE, Thummel KE, Thornton TA, Veenstra DL. VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People. Clin Transl Sci. 2019 Mar 1. PMID: 30821933.
  3. Hendrix N, Ollendorf DA, Chapman RH, Loos A, Liu S, Kumar V, Linder JA, Pearson SD, Veenstra DL. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis. J Manag Care Spec Pharm. 2018 Dec;24(12):1210-1217. PMID: 30479197.
  4. Feero WG, Wicklund CA, Veenstra D. Precision Medicine, Genome Sequencing, and Improved Population Health. JAMA. 2018. PMID: 29547675
  5. Li M, Bennette CS, Amendola LM, Ragan Hart M, Heagerty P, Comstock B, Tarczy-Hornoch P, Fullerton SM, Regier DA, Burke W, Trinidad SB, Jarvik GP, Veenstra DL, Patrick DL. The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation. J Genet Couns. 2018 Sep 1. PMID: 30173308.